Skip to main content
letter
. 2012 Jul 19;107(4):585–587. doi: 10.1038/bjc.2012.318

Table 1. Clinical characteristics.

Variable Statistic Placebo ( N =53) Pyridoxine ( N =53)
Age (years) Mean (s.d.) 70 (10) 70 (9)
  Median 73 72
  Min, Max 42, 87 43, 84
       
Cancer type Breast 34.0% (18/53) 37.7% (20/53)
  Colorectal 66.0% (35/53) 62.3% (33/53)
       
Performance status 1 85.7% (24/28) 88.0% (22/25)
  2 14.3% (4/28) 12.0% (3/25)
       
Gender Male 37.7% (20/53) 37.7% (20/53)
  Female 62.3% (33/53) 62.3% (33/53)
       
Capecitabine 92–100% 54.7% (29/53) 56.6% (30/53)
starting dose 64–80% 41.5% (22/53) 41.5% (22/53)
(% full dose) No treatment 3.8% (2/53) 1.9% (1/53)